Faron Pharma's Juho Jalkanen on FDA approval for phase III BEXMAB...
Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen talked with Proactive about the latest positive feedback from the US FDA regarding its phase three clinical trial for cancer treatment Bexmarilimab. Dr Jalkanen shared that the US Food & …